Sojournix starts clinical trial of SJX-653 for menopausal hot flashes

24th February 2020 (Last Updated February 24th, 2020 14:48)

Clinical-stage biopharmaceutical firm Sojournix has started a Phase II trial to evaluate the efficacy of SJX-653, a once-daily regimen for moderate to severe vasomotor symptoms (VMS), hot flashes, and night sweats associated with the menopause.

Sojournix starts clinical trial of SJX-653 for menopausal hot flashes
The trial will evaluate SJX-653 in reducing the frequency and severity of VMS. Credit: Darko Stojanovic from Pixabay.

Clinical-stage biopharmaceutical firm Sojournix has started a Phase II trial to evaluate the efficacy of SJX-653, a once-daily regimen for moderate to severe vasomotor symptoms (VMS), hot flashes, and night sweats associated with the menopause.

SJX-653 is a novel, potent, selective neurokinin 3 (NK3) antagonist in clinical development and is used as a non-hormonal treatment for VMS.

Sojournix chief medical officer Ruth Thieroff-Ekerdt said: “Though millions of women suffer from hot flashes, unfortunately, current therapies for VMS often leave women searching for better alternatives.

“Many women choose to avoid hormone therapy, and current non-hormonal options often provide unsatisfactory symptom relief. Women and their doctors need new non-hormonal treatment options with meaningful clinical efficacy, and SJX-653 aims to address this important unmet medical need.”

The 12-week, multi-centered, randomised, double-blind, and placebo-controlled Phase II trial will evaluate SJX-653 in reducing the frequency and severity of VMS due to the menopause and also to improve measures of sleep in the patient.

Under the trial, selected subjects will be randomised to receive one of two doses of SJX-653 or placebo through oral administration each morning.

The trial is expected to enroll about 130 postmenopausal women experiencing moderate to severe VMS.

Sojournix CEO and president Daniel Grau said: “The progression of SJX-653 into this Phase II clinical trial represents a significant milestone in bringing SJX-653 to patients.

“NK3 antagonism is a well-validated mechanism of action, and we believe SJX-653 has the potential to become a new standard of care medicine for menopausal women seeking non-hormonal treatment options for VMS.”